
Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

New studies explore whether metformin, exercise, and GLP-1 drugs can blunt obesity-driven lung cancer risks, with trial results and new human research underway.

Ravi B. Parikh, MD, MPP, discusses how artificial intelligence could shape oncology practice, support personalized treatment decisions, and accelerate clinical research.

Bo Wang, MD, discusses the recent trial findings that he sees as having immediate relevance to oncologists treating lung cancers.

Dr. Paolo Tarantino discusses treatment selection for patients with hormone receptor-positive, HER2-negative advanced breast cancer harboring an activating AKT1 mutation.

Dr. Paolo Tarantino presents a hypothetical case of a 62-year-old postmenopausal woman with hormone receptor-positive, HER2-negative advanced breast cancer.

Jiaxin (Jason) Niu, MD, and Amanda Edmond, PA-C, walk through an 8-week treatment update for a patient on subcutaneous amivantamab plus lazertinib: grade 2 acneiform rash and paronychia by week 3; bilateral lower-extremity edema with low albumin by week 6; and partial response on restaging at week 8.

Amanda Edmond, PA-C, explains that lower-extremity edema from amivantamab, due to its MET-targeting mechanism, does not respond well to diuretics and is primarily managed with dose pausing or dose reduction rather than with medication.

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

Karen E. Knudsen, PhD, discusses the greater significance of the INTerpath-001 results of intismeran autogene in resectable melanoma.

Kohei Shitara, MD, discusses safety and tolerability findings from G-HOPE-001 evaluating arcotatug tavatecan in previously treated, CLDN18.2-positive advanced gastric cancer.

Benjamin Garmezy, MD, discusses how JNJ-6143 uses a novel RIPTAC mechanism to target AR and BRD4, potentially addressing resistance-associated genomic alterations in advanced prostate cancer.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, explains the significance of OrigAMI-5's all-comer design, which enrolls patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) regardless of PD-L1 combined positive score (CPS), using local CPS testing only for stratification rather than eligibility.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses the rationale for the phase 3 OrigAMI-5 study, which evaluates amivantamab earlier, in the first-line setting, in combination with pembrolizumab and carboplatin.

Kohei Shitara, MD, discusses HERIZON-GEA-01 findings and how to individualize first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

The oncologist discusses resistance mechanisms and the need to evaluate whether investigational JNJ-6143 can provide durable responses in earlier prostate cancer treatment settings.

Matthew A. Gubens, MD, MS, Julia K. Rotow, MD, and Estelamari Rodriguez, MD, MPH, discuss how intracranial activity shapes treatment in ROS1-positive non-small cell lung cancer (NSCLC), a disease with tropism for the brain.

Ana I. Velázquez Mañana, MD, MSc, describes how she discusses durability of benefit with patients who have ROS1-positive non-small cell lung cancer (NSCLC) while many trials remain ongoing.

Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.

Bo Wang, MD, discusses the positive outcomes for divarasib vs other KRAS G12C inhibitors in non–small cell lung cancer.

Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.

Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.

Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.

Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.

Halfdan Sørbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.

Toni Choueiri, MD, discusses KEYNOTE-564 subgroup findings, adjuvant pembrolizumab after nephrectomy, overtreatment risks, and emerging biomarkers in renal cell carcinoma.

Explore how tissue biopsies and ctDNA blood tests reveal tumor genetics in metastatic breast cancer, with liquid biopsy offering easier, broader insights.

Learn how to anticipate, monitor, and manage PI3K/AKT therapy side effects in advanced HR-positive, HER2-negative breast cancer after CDK4/6 failure.